1. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. Issue 3 (3rd March 2016) Authors: Pantani, L.; Brioli, A.; Tacchetti, P.; Zannetti, B.A.; Mancuso, K.; Rocchi, S.; Martello, M.; Rizzello, I.; Terragna, C.; Zamagni, E.; Cavo, M. Journal: Expert review of hematology Issue: Volume 9:Issue 3(2016) Page Start: 315 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Multiple myeloma: disease response assessment. Issue 9 (1st September 2016) Authors: Zamagni, E.; Tacchetti, P.; Terragna, C.; Cavo, M. Journal: Expert review of hematology Issue: Volume 9:Issue 9(2016) Page Start: 831 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS. (23rd June 2022) Authors: Martino, E. A.; Conticello, C.; Zamagni, E.; Pavone, V.; Palmieri, S.; Musso, M.; Tacchetti, P.; Mele, A.; Catlano, L.; Vigna, E.; Bruzzese, A.; Mendicino, F.; Botta, C.; Vincelli, D.; Farina, G.; Barone, M.; Cangialosi, C.; Mancuso, K.; Rizziello, I.; Rocchi, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 784 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S174: HIGH LEVEL OF CIRCULATING TUMOUR DNA AT DIAGNOSIS CORRELATES WITH DISEASE SPREADING AND DEFINES MULTIPLE MYELOMA PATIENTS WITH POOR PROGNOSIS. (23rd June 2022) Authors: Martello, M.; Poletti, A.; Bezzi, D.; Borsi, E.; Taurisano, B.; Solli, V.; Armuzzi, S.; Vigliotta, I.; Mazzocchetti, G.; Pistis, I.; Pantani, L.; Rocchi, S.; Mancuso, K.; Tacchetti, P.; Rizzello, I.; Cavo, M.; Zamagni, E.; Nanni, C.; Terragna, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗